Quantitative analysis of HBY 097 and its metabolites in human serum and urine by HPLC

Journal of Pharmaceutical and Biomedical Analysis

Volumn 16, Issue 7, 1998, Pages 1195-1203

  Agarwal, V K ^a   Krol, G J ^a   Krone, V ^b   Roberts, D ^a  

^a BAYER CORPORATION   (United States)

^b SANOFI   (France)

Author keywords

Analysis of serum and urine; HBY 097; HPLC; Metabolites of HBY 097; On line sample enrichment; Reverse transcriptase inhibitor

Indexed keywords

RNA DIRECTED DNA POLYMERASE INHIBITOR; TALVIRALINE;

ACCURACY; ANALYTIC METHOD; ARTICLE; DRUG ANALYSIS; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG METABOLISM; DRUG SAFETY; DRUG URINE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; PRIORITY JOURNAL;

ANTIVIRAL AGENTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HUMANS; MODELS, CHEMICAL; QUINOXALINES; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE INHIBITORS; SENSITIVITY AND SPECIFICITY;

EID: 0032031445     PISSN: 07317085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0731-7085(97)00259-8     Document Type: Article

References (3)

1. [1] J. Kleim, M. Rosener, I. Winkler, A. Paessens, R. Kirsch, Y. Hsiou, E. Arnold, G. Riess, Proc. Natl. Acad. Sci. 93 (1996) 34-38.
2. [2] A. Shah, K. Kumor, J. Sullivan, R. Amand, V. Agarwal, G. Krol, E. Huguenel, J. R. Suarez, A. H. Heller, XI International Conference on Aids, Vancouver, Canada, July 7-12, 1996.
3. [3] V. Krone, HMR Preclinical Development, Hoechst, Frankfurt, Germany, Internal Report, February 1997.